Aspreva Pharmaceuticals   Report issue

For profit Phase 3
Founded: Victoria BC Canada (2001)
Status: Acquired by Vifor Inc. (2007) → now CSL Behring (2021)

Organization Overview

First Clinical Trial
2004
NCT00683930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Nephritis (Phase 3)

Multiple Sclerosis (Phase 2)

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Nephritis (Phase 3)

Pemphigus (Phase 3)

Scleroderma, Diffuse (Phase 1)

Scleroderma, Systemic (Phase 1)

Sclerosis (Phase 2)

Vasculitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4